Curcumin glucuronide is under clinical development by TheraBioPharma and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Curcumin glucuronide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Curcumin glucuronide overview
Curcumin glucuronide is under development for the treatment of colon cancer, multiple myeloma, glioblastoma, colorectal cancer, covid-19, cytokine release syndrome, osteoarthritis of the knee. The drug candidate is administered through intravenous and oral route.
TheraBioPharma overview
TheraBioPharma focuses on research and the development of functional materials, pharmaceutical products for treatments, and diagnostic systems. TheraBioPharma is headquartered in Kawasaki, Kanagawa, Japan.
For a complete picture of Curcumin glucuronide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
